Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind Phase III Study of the Effect of First-Line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-Free Survival in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer

Next Previous
Search
Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Phase III Study of the Effect of First-Line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-Free Survival in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FASTACT-2; FASTACT-II
  • Sponsors Roche

    • Most Recent Events

    • 01 Jan 2022 Results assessing circulating tumor DNA incorporation into RECIST to provide a more robust measure of tumor response from FASTACT-2 patients, published in the Lung Cancer
    • 07 Jan 2016 Results of pooled analysis of seven studies published in the Journal of Thoracic Oncology
    • 26 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top